AbCellera Investor Conference Presentation Deck
January 2024, 14 slides
  1. AbCellera
  2. Related Decks
  3. Investor Conference Presentation Decks
corporate overview conference | AbCellera
disclaimer | AbCellera
the most important drivers of productivity in drug development are new insights into the biology of disease novel solutions to challenging problems | AbCellera
we have built an engine to generate first in class and best in class antibody medicines investments in technological capability can improve the productivity of drug development long term value creation comes from being able repeatedly deliver first in class products | AbCellera
engine is broadly applicable within the antibody therapeutics market years of investment in technology teams and infrastructure vertical integration from concept to clinic leading capabilities on difficult targets validated on therapeutic programs and | AbCellera
we are increasingly focused on strategic partnerships expanding relationships cell engager platform development company creation prelude with large and large deals in oncology and conditions to access new targets and technology with top tier venture capital groups | AbCellera
advancing an internal pipeline of potential first in class and best in class assets is a top priority to drive growth first two submissions anticipated in we intend take additional development candidates into enabling studies in in non dilutive funding from governments canada atopic dermatitis or undisclosed | AbCellera
is a potential best in class and second in class antibody therapy for the treatment of atopic dermatitis | AbCellera
a potential first in class antibody therapy for metabolic and endocrine conditions asset derived from our ion channel platform | AbCellera
continued progress and differentiation for cell engager platform improve the safety profile of cell expand the accessible target space for cell in solid tumors have tremendous potential treatment cancer conditions but are technically challenging to design engineer combines unique discovery capabilities engineering a panel hundreds diverse binding antibodies to potentially by creating antibodies that achieve potent tumor killing with reduced release which can help address dose limiting toxicity by enabling discovery antibodies that are highly specific to peptide complexes | AbCellera
reducing dose limiting toxicity associated with release selection of binders that achieve potent cell killing very low on an undisclosed target potent tumor cell killing low | AbCellera
expanding the target space discovery platform enables generation of diverse and highly specific binders a | AbCellera
continued focus on high value programs and strategic partnerships with our differentiated technology position in liquidity we have a long cash runway for focused investment execution completion of engine over the next years we will continue to invest in the final stage of our engine including construction commissioning of our manufacturing facility our portfolio of partnered in we anticipate partnership deals from our cell engager platform our partnership strategy is to select high value not deal volume our portfolio of internal we expect to enter clinical development in in we expect additional first in class development candidates from our ion channel platform | AbCellera
thank you | AbCellera
See More
AbCellera
Investor Conference Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Autoimmune
Drug development
Recent decks by AbCellera
Investor Presentation
February 2024
Results
November 2023
Investor Presentation
November 2023
Investor Presentation
November 2023
See all presentations by AbCellera (23 decks)
Related decks
argenx SE
Results
July 2021
argenx SE
Results
October 2022
argenx SE
Results
July 2023
argenx SE
Investor Presentation
March 2023
ATAI
Investor Presentation
October 2022
ATAI
Investor Day
January 2022
Certara
Investor Day
December 2021
argenx SE
Investor Presentation
November 2023
Recent decks by AbCellera
See all presentations (23 decks)
Investor Presentation
February 2024
Results
November 2023
Investor Presentation
November 2023
Investor Presentation
November 2023
argenx SE
Results
July 2021
argenx SE
Results
October 2022
argenx SE
Results
July 2023
argenx SE
Investor Presentation
March 2023
ATAI
Investor Presentation
October 2022
ATAI
Investor Day
January 2022
Certara
Investor Day
December 2021
argenx SE
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io